Laboratory of Pneumology, Department of Chronic Diseases, Metabolism and Ageing (CHROMETA), KU Leuven, Leuven, Belgium.
Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium.
Respirology. 2018 Dec;23(12):1160-1165. doi: 10.1111/resp.13342. Epub 2018 Jun 13.
Although idiopathic pulmonary fibrosis (IPF) patients experience a worse survival compared with chronic hypersensitivity pneumonitis (CHP), organic dust exposure is a known risk factor for both IPF and CHP.
We divided patients diagnosed with IPF, based on their exposure to moulds/birds (absent: group A; present: group B). We retrospectively compared pulmonary function and survival between groups A and B, and a separate CHP cohort (group C).
A total of 293 patients were included (group A: n = 171, group B: n = 73, group C: n = 49). Demographics and baseline pulmonary function did not differ between groups A and B, but significant differences were seen between groups B and C. Median survival of group B was 84 months, which was longer than group A (43 months, P = 0.002), but lower than group C (157 months, P = 0.04), in both univariate and multivariate analyses. Antifibrotic treatment resulted in a better outcome in group A (hazard ratio (HR): 0.44) and group B (HR: 0.12) without interaction between exposure and antifibrotic use (P = 0.20). Forced vital capacity (FVC) decline was not associated with mould/bird exposure in this cohort.
Group B patients experienced a better outcome compared with (non-exposed) IPF patients, although worse compared with CHP patients. Antifibrotic treatment in group B resulted in a similar beneficial effect compared with group A. Further research is needed to ascertain the diagnostic designation in this exposed usual interstitial pneumonia (UIP) patient group without other CHP features.
虽然特发性肺纤维化(IPF)患者的生存情况比慢性过敏性肺炎(CHP)患者更差,但有机尘埃暴露是 IPF 和 CHP 的已知危险因素。
我们根据患者是否接触霉菌/鸟类(无:A 组;有:B 组)将 IPF 患者进行分组。我们回顾性地比较了 A、B 两组和单独的 CHP 队列(C 组)的肺功能和生存率。
共纳入 293 例患者(A 组:n=171,B 组:n=73,C 组:n=49)。A 组和 B 组患者的人口统计学特征和基线肺功能无差异,但 B 组和 C 组之间存在显著差异。B 组的中位生存时间为 84 个月,长于 A 组(43 个月,P=0.002),但短于 C 组(157 个月,P=0.04),在单因素和多因素分析中均如此。在 A 组(风险比(HR):0.44)和 B 组(HR:0.12)中,抗纤维化治疗均有较好的结果,而暴露与抗纤维化使用之间没有相互作用(P=0.20)。在本队列中,用力肺活量(FVC)下降与霉菌/鸟类暴露无关。
B 组患者的预后较(未暴露)IPF 患者好,但较 CHP 患者差。B 组的抗纤维化治疗与 A 组有相似的获益效果。需要进一步研究来确定这组无其他 CHP 特征但有暴露性寻常型间质性肺炎(UIP)的患者的诊断分类。